New drug combo shows promise in early trial for AML patients
NCT ID NCT04190550
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 26 times
Summary
This early-phase trial is testing whether adding a new drug called navtemadlin to standard chemotherapy can help control acute myeloid leukemia (AML) better than chemo alone. The study involves about 24 adults with newly diagnosed AML and aims to find the safest dose and check for side effects. Navtemadlin works by blocking a protein that helps cancer cells grow, and combining it with chemo may keep the leukemia under control for longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.